Antidepressant brain zaps — why they happen, and how to stop them
"Brain zaps" are brief, jarring electric-shock sensations that travel through the head, sometimes triggered by eye movement. They are the most distinctive — and the most distressing — antidepressant discontinuation symptom. This page explains why they happen, which drugs cause them most, and how a hyperbolic taper resolves them.
What are brain zaps?
Brain zaps (also called "brain shivers", "head zaps", or "electric shocks in the head") are sudden, brief sensations described as electricity travelling through the brain. They often last less than a second, can repeat several times an hour, and are commonly triggered by saccadic eye movements — looking from one side to another. Framer (2021) describes them as one of the hallmark signs that a taper has been too rapid for the nervous system to adapt to the change in receptor occupancy.
Why hyperbolic tapering reduces brain zaps
Antidepressants follow a hyperbolic dose–occupancy curve: even tiny reductions in mg at the bottom of the dose range can produce outsized changes in receptor occupancy (Horowitz & Taylor, 2019). Each large drop in occupancy is what the nervous system registers as "the taper is happening too fast" — and brain zaps are one of the most visible signs of that mismatch. A hyperbolic taper keeps each step's occupancy change roughly constant, which is why brain zaps typically stop within days of moving to the previous stable dose and resuming reductions in smaller percentages.
Which drugs cause brain zaps most often?
- Venlafaxine (Effexor) — short half-life SNRI, the most-cited culprit. Effexor taper guide →
- Paroxetine (Paxil/Seroxat) — short half-life SSRI with the steepest dose–occupancy curve. Paxil taper guide →
- Duloxetine (Cymbalta) — SNRI distributed as enteric-coated pellets; bead counting is the workaround. Cymbalta taper guide →
- Sertraline, escitalopram, citalopram — reported but less common than the three above.
- Fluoxetine (Prozac) — rare, thanks to its long half-life.
Frequently asked questions about brain zaps
Plain-English answers, reviewed by psychiatrists, with citations to the foundational evidence.
What are antidepressant brain zaps?
Brain zaps are brief, jarring electric-shock or "zap" sensations that travel through the head — sometimes triggered by eye movements. They are one of the most distinctive antidepressant discontinuation symptoms and are most often reported with short-half-life SSRIs (paroxetine) and SNRIs (venlafaxine, duloxetine).
How long do brain zaps last after stopping antidepressants?
Brain zaps usually appear within days of a dose reduction or missed dose and settle within 1–3 weeks if the reduction was not too large. They can persist longer when the taper was abrupt; in this case, returning to the previous dose and re-tapering more slowly typically resolves them.
Are brain zaps dangerous?
Brain zaps themselves are not known to be dangerous. They do indicate that the nervous system is reacting to a rapid drop in serotonin transporter occupancy — a sign to slow the taper. Persistent or worsening neurological symptoms (numbness, weakness, seizures) require urgent medical assessment.
How do I get rid of brain zaps during a taper?
The most reliable approach is hyperbolic tapering: take smaller percentage reductions and hold each new dose for 2–4 weeks. If brain zaps appear after a reduction, return to the previous stable dose, let symptoms settle for at least a week, then reduce again with a smaller step using a liquid or compounded preparation.
Which antidepressants are most associated with brain zaps?
Brain zaps are most commonly reported with paroxetine (Paxil/Seroxat), venlafaxine (Effexor), and duloxetine (Cymbalta) — all of which have short half-lives and steep dose-occupancy curves. They are rarer with fluoxetine because its long half-life self-tapers.
Drug-specific brain zaps guidance
Brain zaps risk and dosing tips for every supported medication.
- Taper off Zoloft / Lustralsertraline · SSRI
- Taper off Paxil / Seroxatparoxetine · SSRI
- Taper off Celexa / Cipramilcitalopram · SSRI
- Taper off Lexapro / Cipralexescitalopram · SSRI
- Taper off Prozacfluoxetine · SSRI
- Taper off Luvox / Faverinfluvoxamine · SSRI
- Taper off Effexor / Efexorvenlafaxine · SNRI
- Taper off Cymbaltaduloxetine · SNRI
- Taper off Pristiqdesvenlafaxine · SNRI
- Taper off Savellamilnacipran · SNRI
- Taper off Elavilamitriptyline · TCA
- Taper off Pamelor / Allegronnortriptyline · TCA
- Taper off Anafranilclomipramine · TCA
- Taper off Tofranilimipramine · TCA
- Taper off Prothiadendosulepin · TCA
- Taper off Lomontlofepramine · TCA
- Taper off Remeron / Zispinmirtazapine · NaSSA
- Taper off Trintellix / Brintellixvortioxetine · atypical
- Taper off Wellbutrin / Zybanbupropion · NDRI
- Taper off Desyrel / Molipaxintrazodone · SARI
- Taper off Valdoxanagomelatine · atypical
⚠️ It's not a substitute for medical advice. This calculator can help you visualise a tapering schedule but before making any changes to your medication plan it's necessary to consult a medical professional. Ask a psychiatrist — available after you request your protocol.
This schedule is a map, not a rule. Wait until symptoms from the previous step have settled before reducing again — and review every change with your prescriber.
Clinical references for brain zaps
Foundational pharmacology, withdrawal incidence, and tapering guidance.
- [1]Framer A. What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications. Therapeutic Advances in Psychopharmacology 2021. doi:10.1177/2045125321991274Describes the "windows and waves" pattern of withdrawal recovery and supports patient-led pacing.
- [2]Henssler J et al. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. The Lancet Psychiatry 2024. doi:10.1016/S2215-0366(24)00133-0Meta-analysis of 79 studies (≈21,000 patients): pooled incidence of discontinuation symptoms ~31%; severe symptoms ~2.8%.
- [3]Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry 2019. doi:10.1016/S2215-0366(19)30032-XProposes hyperbolic dose reduction based on receptor-occupancy curves; the methodological basis of every modern taper calculator.
- [4]Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychotherapy and Psychosomatics 2020. doi:10.1159/000506868Taxonomy distinguishing new withdrawal symptoms, rebound, and persistent post-withdrawal disorder; the standard framework for withdrawal vs. relapse.
- [5]Horowitz MA, Taylor D. The Maudsley Deprescribing Guidelines. Wiley 2024. doi:10.1002/9781394291052Per-drug operational manual for hyperbolic tapering across SSRIs, SNRIs, benzodiazepines, gabapentinoids, and antipsychotics.
- [6]National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. NICE guideline [NG222]. NICE 2022. LinkUK national guideline endorsing proportional (hyperbolic) tapering and the use of liquid formulations to enable small final doses.
Claro mobile app
Catch a flare-up before it derails your taper.
The Claro app checks in daily, flags symptom patterns that suggest a step was too fast, and tells you when to hold or talk to a prescriber. Built with psychiatrists; based on the same evidence as this page.
If you are in crisis or having thoughts of suicide, do not wait for an email response. Find a crisis helpline near you immediately →